Non-Coding RNAs: Regulating Disease Progression and Therapy Resistance in Hepatocellular Carcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 May 21

PMID 32429062

Citations 11

Authors

Debashri Manna

Devanand Sarkar

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC), the primary liver cancer arising from hepatocytes, is a universal health problem and one of the most common malignant tumors. Surgery followed by chemotherapy as well as tyrosine kinase inhibitors (TKIs), such as sorafenib, are primary treatment procedures for HCC, but recurrence of disease because of therapy resistance results in high mortality. It is necessary to identify novel regulators of HCC for developing effective targeted therapies that can significantly interfere with progression of the disease process. Non-coding RNAs (ncRNAs) are an abundant group of versatile RNA transcripts that do not translate into proteins, rather serve as potentially functional RNAs. The role of ncRNAs in regulating diverse aspects of the carcinogenesis process are gradually being elucidated. Recent advances in RNA sequencing technology have identified a plethora of ncRNAs regulating all aspects of hepatocarcinogenesis process and serving as potential prognostic or diagnostic biomarkers. The present review provides a comprehensive description of the biological roles of ncRNAs in disease process and therapy resistance, and potential clinical application of these ncRNAs in HCC.

Citing Articles

The lncRNA Gm8097 is associated with hypospermatogenesis.

Lei B, Ye L, Qiu Z, Zhang S Clin Exp Reprod Med. 2024; 51(4):314-323.

PMID: 38853128 PMC: 11617910. DOI: 10.5653/cerm.2024.06835.

Databases and prospects of dynamic gene regulation in eukaryotes: A mini review.

Chow C, Yang C, Chang W Comput Struct Biotechnol J. 2023; 21:2147-2159.

PMID: 37013004 PMC: 10066511. DOI: 10.1016/j.csbj.2023.03.032.

Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.

Tao S, Liang S, Zeng T, Yin D Front Immunol. 2023; 13:1043667.

PMID: 36685594 PMC: 9845774. DOI: 10.3389/fimmu.2022.1043667.

Persistent epigenetic alterations in transcription factors after a sustained virological response in hepatocellular carcinoma.

Sugimachi K, Araki H, Saito H, Masuda T, Miura F, Inoue K JGH Open. 2022; 6(12):854-863.

PMID: 36514506 PMC: 9730721. DOI: 10.1002/jgh3.12833.

Noncoding RNA-mediated regulation of pyroptotic cell death in cancer.

Wang M, Zhang Y, Chang W, Zhang L, Syrigos K, Li P Front Oncol. 2022; 12:1015587.

PMID: 36387211 PMC: 9659888. DOI: 10.3389/fonc.2022.1015587.

References

Cui M, Zheng M, Sun B, Wang Y, Ye L, Zhang X . A long noncoding RNA perturbs the circadian rhythm of hepatoma cells to facilitate hepatocarcinogenesis. Neoplasia. 2015; 17(1):79-88. PMC: 4309731. DOI: 10.1016/j.neo.2014.11.004. View

Takahashi K, Yan I, Wood J, Haga H, Patel T . Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res. 2014; 12(10):1377-87. PMC: 4201956. DOI: 10.1158/1541-7786.MCR-13-0636. View

Lim L, Wong S, Huang F, Lim S, Chong S, Ooi L . Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma. Cancer Res. 2019; 79(20):5131-5139. DOI: 10.1158/0008-5472.CAN-19-0255. View

Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

DU Y, Kong G, You X, Zhang S, Zhang T, Gao Y . Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem. 2012; 287(31):26302-11. PMC: 3406714. DOI: 10.1074/jbc.M112.342113. View

Zhang X, Zhou J, Lu X . The long noncoding RNA NEAT1 contributes to hepatocellular carcinoma development by sponging miR-485 and enhancing the expression of the STAT3. J Cell Physiol. 2017; 233(9):6733-6741. DOI: 10.1002/jcp.26371. View

Chen L, Yao H, Wang K, Liu X . Long Non-Coding RNA MALAT1 Regulates ZEB1 Expression by Sponging miR-143-3p and Promotes Hepatocellular Carcinoma Progression. J Cell Biochem. 2017; 118(12):4836-4843. DOI: 10.1002/jcb.26158. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Zhu A, Kang Y, Yen C, Finn R, Galle P, Llovet J . Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2):282-296. DOI: 10.1016/S1470-2045(18)30937-9. View

10.

Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C . MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. PLoS One. 2014; 9(12):e115565. PMC: 4274118. DOI: 10.1371/journal.pone.0115565. View

11.

Tsai W, Hsu S, Hsu C, Lai T, Chen S, Shen R . MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012; 122(8):2884-97. PMC: 3408747. DOI: 10.1172/JCI63455. View

12.

Xiong H, Ni Z, Jiang S, Li X, He J, Gong W . LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. 2017; 36(25):3528-3540. DOI: 10.1038/onc.2016.521. View

13.

Yang T, He X, Chen A, Tan K, Du X . RETRACTED: LncRNA HOTAIR contributes to the malignancy of hepatocellular carcinoma by enhancing epithelial-mesenchymal transition via sponging miR-23b-3p from ZEB1. Gene. 2018; 670:114-122. DOI: 10.1016/j.gene.2018.05.061. View

14.

Guo S, Chen W, Luo Y, Ren F, Zhong T, Rong M . Clinical implication of long non-coding RNA NEAT1 expression in hepatocellular carcinoma patients. Int J Clin Exp Pathol. 2015; 8(5):5395-402. PMC: 4503113. View

15.

Pan C, Wang X, Shi K, Zheng Y, Li J, Chen Y . MiR-122 Reverses the Doxorubicin-Resistance in Hepatocellular Carcinoma Cells through Regulating the Tumor Metabolism. PLoS One. 2016; 11(5):e0152090. PMC: 4854441. DOI: 10.1371/journal.pone.0152090. View

16.

Luna J, Barajas J, Teng K, Sun H, Moore M, Rice C . Argonaute CLIP Defines a Deregulated miR-122-Bound Transcriptome that Correlates with Patient Survival in Human Liver Cancer. Mol Cell. 2017; 67(3):400-410.e7. PMC: 5603316. DOI: 10.1016/j.molcel.2017.06.025. View

17.

Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S . MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2009; 69(14):5761-7. DOI: 10.1158/0008-5472.CAN-08-4797. View

18.

Chen L . The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016; 17(4):205-11. DOI: 10.1038/nrm.2015.32. View

19.

Fang X, Yang D, Luo H, Wu S, Dong W, Xiao J . SNORD126 promotes HCC and CRC cell growth by activating the PI3K-AKT pathway through FGFR2. J Mol Cell Biol. 2016; 9(3):243-255. DOI: 10.1093/jmcb/mjw048. View

20.

Cao F, Yin L . miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway. Exp Mol Pathol. 2018; 106:34-43. DOI: 10.1016/j.yexmp.2018.10.009. View